Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
Michael J. Mullen, Xu Yu Jin, Anne H. Child, Graham Stuart et autres
BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with …
gb, se, cn, us, tr (code pays fourni par la source)